

EMR cumulative indigenous Measles/Rubella cases counts and surveillance indicators

Between 01/01/2020 and 31/01/2020

Country	Measles case finding report							Rubella case finding report						Measles incidence/1000 * 0,000	Rubella incidence/100,000 **	Reporting rate ***	Indicators: target ≥80%					Last date reported	Genotypes reorted
	Total suspected cases for M/R	Specimens tested for Measles	Measles lab confirmed	Measles Epi-Linked	Measles clinically compatible	Total Measles	Measles discarded cases	Specimens tested for Rubella	Rubella lab confirmed	Rubella Epi-Linked	Rubella clinically compatible	Total Rubella	Rubella discarded				suspects tested for Measles ****	cases with complete investigation	specimens received at the lab within 5 days	specimens with adequate condition	results reported back within 4 days		
Afghanistan	14	14	2	0	0	2	8	12	4	0	0	4	8	0.06	0.12	0.02	100%	100%	29%	100%	100%	31/01/2020	
Bahrain	29	29	0	0	0	0	29	29	0	0	0	0	29	0.00	0.00	1.93	100%	100%	100%	100%	100%	31/01/2020	
Djibouti																							
Iran	375	351	0	0	0	0	348	351	0	0	0	0	351	0.00	0.00	0.47	94%	51%	89%	100%	92%	31/01/2020	
Iraq																							
Jordan	4	4	0	0	0	0	4	3	0	0	0	0	3	0.00	0.00	0.04	100%	75%	100%	100%	75%	07/01/2020	
Egypt	154	154	0	0	0	0	152	154	0	0	0	0	154	0.00	0.00	0.16	100%	100%	99%	100%	73%	31/01/2020	
Kuwait	3	3	0	0	0	0	3	3	0	0	0	0	3	0.00	0.00	0.07	100%	100%	100%	100%	0%	15/01/2020	
Lebanon	13	9	0	0	4	4	9	9	0	0	0	0	9	0.70	0.00	0.16	69%	100%	38%	100%	0%	30/01/2020	
Libya	69	69	8	0	0	8	61	69	2	0	0	2	67	1.15	0.29	0.85	100%	100%	25%	100%	93%	31/01/2020	
Morocco	21	21	3	0	0	3	17	15	1	0	0	1	14	0.09	0.03	0.05	100%	100%	100%	100%	100%	29/01/2020	
Oman	119	116	0	0	0	0	118	116	0	0	0	0	116	0.00	0.00	2.61	97%	99%	92%	100%	88%	31/01/2020	B3 imp.
Pakistan	656	436	181	20	47	248	396	435	5	0	0	5	430	1.16	0.02	0.19	69%	94%	53%	92%	90%	31/01/2020	
Palestine	17	17	0	0	0	0	17	17	0	0	0	0	17	0.00	0.00	0.36	100%	59%	82%	100%	100%	13/01/2020	
Qatar	9	9	1	0	0	1	7	5	0	0	0	0	5	0.37	0.00	0.29	100%	100%	89%	100%	63%	23/01/2020	
Saudi Arabia	62	62	5	0	0	5	53	62	4	0	0	4	58	0.15	0.12	0.16	100%	95%	100%	100%	100%	31/01/2020	
Somalia ★	300	0	0	0	300	300	0	0	0	0	0	0	0	21.57	0.00	0.00	0%	0%	0%	0%	0%	31/01/2020	
Sudan	135	86	14	26	0	40	74	82	25	0	0	25	57	0.86	0.54	0.15	79%	99%	90%	93%	92%	30/01/2020	
Syria	61	61	0	0	0	0	60	61	0	0	0	0	61	0.00	0.00	0.25	100%	100%	51%	100%	98%	31/01/2020	
Tunisia	105	92	2	0	18	20	76	92	7	0	0	7	85	1.75	0.61	0.68	88%	89%	57%	100%	96%	31/01/2020	
UAE	20	20	3	0	0	3	16	20	1	0	0	1	19	0.33	0.11	0.18	100%	100%	90%	100%	100%	28/01/2020	
Yemen																							
Total	2166	1553	219	46	369	634	1448	1535	49	0	0	49	1486	0.94	0.07	0.24	85%	92%	77%	98%	81%		

*The sum of the measles lab confirmed cases +measles epi-linked cases + measles clinically compatible cases/million population
 **The sum of the rubella lab confirmed cases +rubella epi-linked cases + rubella clinically compatible cases/million population
 ***Reporting rate of discarded non-measles non-rubella cases at the national level per 100,000 total population
 ****Excluding measles and rubella epi-linked cases

Green cells= indicator met.
 Yellow cells=indicator not met.
 Red cells=missing data for calculating indicator.

Adequate investigation includes the following data elements:
 -District. -Age. -Gender.
 -Date of rash onset, case notification and investigation
 -Vaccination status. -Date of last vaccination with MCV
 -Date specimen collected.
 -Travel history

Countries that did not report

★ **Somalia reported aggregate data**

Measles final classification and distribution by Month

Between 01/01/2020 and 31/01/2020

Country	Total Suspected cases for measles	Total specimens tested	Measles positive ELISA	Imported Measles cases	Measles import related	Unknown source	Vaccine related	Pending result	Measles Lab confirmed	Measles Epi-Linked	Measles clinically compatible	Total Measles	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
Afghanistan	14	14	2	0	0	0	0	0	2	0	0	2	2											
Bahrain	29	29	0	0	0	0	0	0	0	0	0	0	0											
Djibouti																								
Iran	375	351	9	0	0	0	8	0	0	0	0	0	0											
Iraq																								
Jordan	4	4	1	0	0	0	0	0	0	0	0	0	0											
Egypt	154	154	0	0	0	0	0	2	0	0	0	0	0											
Kuwait	3	3	0	0	0	0	0	0	0	0	0	0	0											
Lebanon	13	9	0	0	0	0	0	0	0	0	4	4	4											
Libya	69	69	8	0	0	0	0	0	8	0	0	8	8											
Morocco	21	21	3	0	0	0	0	0	3	0	0	3	3											
Oman	119	116	4	0	1	0	0	0	0	0	0	0	0											
Pakistan	656	436	191	0	0	0	0	5	181	20	47	248	248											
Palestine	17	17	0	0	0	0	0	0	0	0	0	0	0											
Qatar	9	9	2	1	0	0	0	0	1	0	0	1	1											
Saudi Arabia	62	62	5	0	0	0	0	0	5	0	0	5	5											
Somalia	300	0	0	0	0	0	0	0	0	0	300	300	300											
Sudan	135	86	14	0	0	0	0	0	14	26	0	40	40											
Syria	61	61	0	0	0	0	0	0	0	0	0	0	0											
Tunisia	105	92	4	0	0	0	1	0	2	0	18	20	20											
UAE	20	20	3	0	0	0	0	0	3	0	0	3	3											
Yemen																								
Total	2166	1553	246	1	1	0	9	7	219	46	369	634	634											



* Imported measles/rubella case – a case exposed to measles outside the country during the 7-21 days prior to rash onset and supported by epidemiological or virological evidence (for rubella the exposure would be during the 12-23 days prior to rash onset)

** Importation related measles/rubella case – a locally acquired infection occurring as part of a chain of transmission originating from an imported case as supported by epidemiological or virological evidence

***Vaccine related case – a suspect case that has a rash like illness without respiratory symptoms and the rash had onset 7-14 days following vaccination and the lab detected IgM in the blood specimen that was collected 8-56 days after vaccination and there were no secondary cases identified. OR any suspect case from which virus is isolated and genotyping test reveals the virus to be a vaccine strain

Total confirmed cases; include all cases confirmed by laboratory testing or epi linkage, plus those clinical cases that were reported without a laboratory specimen or epi linkage

Cumulative geographic distribution of Measles cases in the EMR countries January 2020



Rubella final classification and distribution by Month

Between 01/01/2020 and 31/01/2020

Country	Total Suspected cases for Rubella	Total specimens tested	Rubella positive ELISA	Imported Rubella cases	Rubella import related	Unknown source	Vaccine related	Pending result	Rubella Lab confirmed	Rubella Epi Linked	Rubella clinically compatible	Total Rubella	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
Afghanistan	14	12	4	0	0	0	0	0	4	0	0	4	4											
Bahrain	29	29	0	0	0	0	0	0	0	0	0	0	0											
Djibouti																								
Iran	375	351	0	0	0	0	0	0	0	0	0	0	0											
Iraq																								
Jordan	4	3	0	0	0	0	0	0	0	0	0	0	0											
Egypt	154	154	2	0	0	0	0	2	0	0	0	0	0											
Kuwait	3	3	0	0	0	0	0	0	0	0	0	0	0											
Lebanon	13	9	0	0	0	0	0	0	0	0	0	0	0											
Libya	69	69	2	0	0	0	0	0	2	0	0	2	2											
Morocco	21	15	1	0	0	0	0	0	1	0	0	1	1											
Oman	119	116	3	0	0	0	0	0	0	0	0	0	0											
Pakistan	656	435	5	0	0	0	0	5	5	0	0	5	5											
Palestine	17	17	0	0	0	0	0	0	0	0	0	0	0											
Qatar	9	5	0	0	0	0	0	0	0	0	0	0	0											
Saudi Arabia	62	62	4	0	0	0	0	0	4	0	0	4	4											
Somalia	300	0	0	0	0	0	0	0	0	0	0	0	0											
Sudan	135	82	25	0	0	0	0	0	25	0	0	25	25											
Syria	61	61	0	0	0	0	1	0	0	0	0	0	0											
Tunisia	105	92	8	0	0	0	1	0	7	0	0	8	8											
UAE	20	20	1	0	0	0	0	0	1	0	0	1	1											
Yemen																								
Total	2166	1535	55	0	0	0	2	7	49	0	0	50	50											


* Imported measles/rubella case – a case exposed to measles outside the country during the 7-21 days prior to rash onset and supported by epidemiological or virological evidence (for rubella the exposure would be during the 12-23 days prior to rash onset)

** Importation related measles/rubella case – a locally acquired infection occurring as part of a chain of transmission originating from an imported case as supported by epidemiological or virological evidence

***Vaccine related case – a suspect case that has a rash like illness without respiratory symptoms and the rash had onset 7-14 days following vaccination and the lab detected IgM in the blood specimen that was collected 8-56 days after vaccination and there were no secondary cases identified. OR any suspect case from which virus is isolated and genotyping test reveals the virus to be a vaccine strain

Total confirmed cases; include all cases confirmed by laboratory testing or epi linkage, plus those clinical cases that were reported without a laboratory specimen or epi linkage

Cumulative geographic distribution of Rubella cases in the EMR countries January 2020



- ▲ Lab confirmed
- EPI linked
- Clinically compatible



Measles and Rubella laboratory summary report

Between 01/01/2020 and 31/01/2020

Country	Measles								Rubella								Reported to EPI within 4days
	specimens tested	%	Positive	%	Negative	%	Equivocal	%	specimens tested	%	Positive	%	Negative	%	Equivocal	%	
Afghanistan	14	100%	2	14%	12	86%	0	0%	12	86%	4	33%	8	67%	0	0%	100%
Bahrain	29	100%	0	0%	29	100%	0	0%	29	100%	0	0%	29	100%	0	0%	100%
Iran	351	94%	9	3%	342	97%	0	0%	351	94%	0	0%	351	100%	0	0%	92%
Jordan	4	100%	1	25%	3	75%	0	0%	3	75%	0	0%	3	100%	0	0%	75%
Egypt	154	100%	0	0%	154	100%	0	0%	154	100%	2	1%	152	99%	0	0%	73%
Kuwait	3	100%	0	0%	3	100%	0	0%	3	100%	0	0%	3	100%	0	0%	
Lebanon	9	69%	0	0%	9	100%	0	0%	9	69%	0	0%	9	100%	0	0%	
Libya	69	100%	8	12%	61	88%	0	0%	69	100%	2	3%	62	90%	5	7%	93%
Morocco	21	100%	3	14%	18	86%	0	0%	15	71%	1	7%	14	93%	0	0%	100%
Oman	116	97%	4	3%	110	95%	2	2%	116	97%	3	3%	112	97%	1	1%	88%
Pakistan	436	66%	191	44%	221	51%	24	6%	435	66%	5	1%	405	93%	25	6%	90%
Palestine	17	100%	0	0%	17	100%	0	0%	17	100%	0	0%	17	100%	0	0%	100%
Qatar	9	100%	2	22%	7	78%	0	0%	5	56%	0	0%	5	100%	0	0%	63%
Saudi Arabia	62	100%	5	8%	57	92%	0	0%	62	100%	4	6%	58	94%	0	0%	100%
Sudan	86	64%	14	16%	72	84%	0	0%	82	61%	25	30%	57	70%	0	0%	92%
Syria	61	100%	0	0%	61	100%	0	0%	61	100%	0	0%	60	98%	1	2%	98%
Tunisia	92	88%	4	4%	87	95%	1	1%	92	88%	8	9%	77	84%	7	8%	96%
UAE	20	100%	3	15%	16	80%	1	5%	20	100%	1	5%	18	90%	1	5%	100%